London
· Delayed Price · Currency is GBP · Price in USD OncoCyte Statistics
Total Valuation
OncoCyte has a market cap or net worth of GBP 73.92 million. The enterprise value is 70.18 million.
| Market Cap | 73.92M |
| Enterprise Value | 70.18M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +70.84% |
| Shares Change (QoQ) | +26.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 10.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.20 |
| PB Ratio | -7.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.16, with an EV/FCF ratio of -4.14.
| EV / Earnings | -1.44 |
| EV / Sales | 49.66 |
| EV / EBITDA | 0.16 |
| EV / EBIT | n/a |
| EV / FCF | -4.14 |
Financial Position
The company has a current ratio of 1.62
| Current Ratio | 1.62 |
| Quick Ratio | 1.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.01 |
| Debt / FCF | -0.17 |
| Interest Coverage | -276.75 |
Financial Efficiency
Return on equity (ROE) is -910.86% and return on invested capital (ROIC) is -146.37%.
| Return on Equity (ROE) | -910.86% |
| Return on Assets (ROA) | -26.42% |
| Return on Invested Capital (ROIC) | -146.37% |
| Return on Capital Employed (ROCE) | -83.60% |
| Revenue Per Employee | 31,302 |
| Profits Per Employee | -1.01M |
| Employee Count | 49 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.70% in the last 52 weeks. The beta is 1.01, so OncoCyte's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +23.70% |
| 50-Day Moving Average | 2.63 |
| 200-Day Moving Average | 10.92 |
| Relative Strength Index (RSI) | 62.28 |
| Average Volume (20 Days) | 361 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.77 |
Income Statement
In the last 12 months, OncoCyte had revenue of GBP 1.50 million and -48.67 million in losses. Loss per share was -3.72.
| Revenue | 1.50M |
| Gross Profit | 661,382 |
| Operating Income | -18.57M |
| Pretax Income | -48.46M |
| Net Income | -48.67M |
| EBITDA | -17.32M |
| EBIT | -18.57M |
| Loss Per Share | -3.72 |
Balance Sheet
The company has 6.90 million in cash and 2.93 million in debt, giving a net cash position of 3.97 million.
| Cash & Cash Equivalents | 6.90M |
| Total Debt | 2.93M |
| Net Cash | 3.97M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -9.80M |
| Book Value Per Share | -0.56 |
| Working Capital | 3.58M |
Cash Flow
In the last 12 months, operating cash flow was -16.54 million and capital expenditures -412,165, giving a free cash flow of -16.96 million.
| Operating Cash Flow | -16.54M |
| Capital Expenditures | -412,165 |
| Free Cash Flow | -16.96M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 44.02% |
| Operating Margin | -1,235.89% |
| Pretax Margin | -3,225.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -70.84% |
| Shareholder Yield | -70.84% |
| Earnings Yield | -65.84% |
| FCF Yield | -22.94% |
Stock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
OncoCyte has an Altman Z-Score of -15.51. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.51 |
| Piotroski F-Score | n/a |